Waters stock price target lowered to $333 from $375 at TD Cowen

TD Cowen reduced its price target on Waters Corp. (WAT) to $333 from $375, maintaining a Hold rating, as the stock trades near its 52-week low following the announcement of its $17.5 billion Reverse Morris Trust merger with Becton Dickinson's biosciences and diagnostic units. This transformative deal, expected to close by Q1 2026, is projected to double Waters' addressable market and be accretive to adjusted EPS with significant synergy targets, though it has generated mixed analyst reactions and added investment thesis complexity. While TD Cowen anticipates strong Q2 organic growth for Waters, investor focus remains on the deal's implications and how upcoming results will be received after the recent sell-off.

Analysis

Waters Corp. (WAT) is currently at a pivotal juncture, with its stock trading near a 52-week low after a 17% decline following the announcement of a transformative merger with Becton Dickinson's biosciences units. This market reaction reflects investor uncertainty despite the deal's strong strategic rationale. The $17.5 billion Reverse Morris Trust transaction is projected to double Waters' total addressable market to approximately $40 billion and be accretive to adjusted EPS in the first year, with mid-teens annualized growth targeted over five years and $345 million in EBITDA synergies by 2030. However, the deal adds significant complexity, as noted by Stifel, and has elicited mixed analyst ratings, with price targets ranging from $330 to $400. TD Cowen, while cutting its price target to $333, maintains a Hold rating and anticipates potential near-term upside, forecasting that Q2 organic growth could meet or exceed the high end of the 5-7% guidance due to drivers like PFAS and pharmaceutical-related demand. The market is thus weighing the substantial long-term value creation potential of the merger against the immediate execution risks and a lengthy closing timeline extending to Q1 2026.

Key Decisions for Investors

• Investors should assess whether the stock's 17% sell-off on deal complexity presents a strategic entry point, given the merger's potential to double the addressable market and be significantly accretive to long-term earnings.
• The upcoming quarterly report is a critical near-term catalyst; organic growth exceeding the company's 5-7% guidance would validate underlying business strength and could counter the current negative sentiment.
• Positions in Waters should account for a long holding period and integration risk, as the merger's closure is not expected until Q1 2026 and is contingent on regulatory and shareholder approvals.